BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

898 related articles for article (PubMed ID: 28692710)

  • 1. Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging.
    Mielke MM; Hagen CE; Wennberg AMV; Airey DC; Savica R; Knopman DS; Machulda MM; Roberts RO; Jack CR; Petersen RC; Dage JL
    JAMA Neurol; 2017 Sep; 74(9):1073-1080. PubMed ID: 28692710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.
    Winer JR; Maass A; Pressman P; Stiver J; Schonhaut DR; Baker SL; Kramer J; Rabinovici GD; Jagust WJ
    JAMA Neurol; 2018 Feb; 75(2):227-235. PubMed ID: 29228071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
    Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
    JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment.
    Kern S; Syrjanen JA; Blennow K; Zetterberg H; Skoog I; Waern M; Hagen CE; van Harten AC; Knopman DS; Jack CR; Petersen RC; Mielke MM
    JAMA Neurol; 2019 Feb; 76(2):187-193. PubMed ID: 30419087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia.
    Oikonomidi A; Tautvydaitė D; Gholamrezaee MM; Henry H; Bacher M; Popp J
    J Alzheimers Dis; 2017; 60(1):273-281. PubMed ID: 28826184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
    Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Leptin and Alzheimer Protein Pathologies Among Older Adults.
    Lee S; Byun MS; Yi D; Ahn H; Jung G; Jung JH; Chang YY; Kim K; Choi H; Choi J; Lee JY; Kang KM; Sohn CH; Lee YS; Kim YK; Lee DY;
    JAMA Netw Open; 2024 May; 7(5):e249539. PubMed ID: 38700863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Aβ42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment.
    Chen TB; Lee YJ; Lin SY; Chen JP; Hu CJ; Wang PN; Cheng IH
    Sci Rep; 2019 Sep; 9(1):13984. PubMed ID: 31562355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Olfactory Dysfunction and Amnestic Mild Cognitive Impairment and Alzheimer Disease Dementia.
    Roberts RO; Christianson TJ; Kremers WK; Mielke MM; Machulda MM; Vassilaki M; Alhurani RE; Geda YE; Knopman DS; Petersen RC
    JAMA Neurol; 2016 Jan; 73(1):93-101. PubMed ID: 26569387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients.
    Mendes AJ; Ribaldi F; Lathuiliere A; Ashton NJ; Zetterberg H; Abramowicz M; Scheffler M; Assal F; Garibotto V; Blennow K; Frisoni GB
    Alzheimers Res Ther; 2024 May; 16(1):110. PubMed ID: 38755703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
    de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
    Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.
    Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS;
    JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting.
    Roberts RO; Aakre JA; Kremers WK; Vassilaki M; Knopman DS; Mielke MM; Alhurani R; Geda YE; Machulda MM; Coloma P; Schauble B; Lowe VJ; Jack CR; Petersen RC
    JAMA Neurol; 2018 Aug; 75(8):970-979. PubMed ID: 29710225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology.
    Kleinschmidt M; Schoenfeld R; Göttlich C; Bittner D; Metzner JE; Leplow B; Demuth HU
    J Alzheimers Dis; 2016; 50(1):111-26. PubMed ID: 26639953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes.
    Pase MP; Beiser AS; Himali JJ; Satizabal CL; Aparicio HJ; DeCarli C; Chêne G; Dufouil C; Seshadri S
    JAMA Neurol; 2019 May; 76(5):598-606. PubMed ID: 30830207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals.
    Mormino EC; Papp KV; Rentz DM; Schultz AP; LaPoint M; Amariglio R; Hanseeuw B; Marshall GA; Hedden T; Johnson KA; Sperling RA
    JAMA Neurol; 2016 Oct; 73(10):1185-1191. PubMed ID: 27548655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.
    Jack CR; Wiste HJ; Therneau TM; Weigand SD; Knopman DS; Mielke MM; Lowe VJ; Vemuri P; Machulda MM; Schwarz CG; Gunter JL; Senjem ML; Graff-Radford J; Jones DT; Roberts RO; Rocca WA; Petersen RC
    JAMA; 2019 Jun; 321(23):2316-2325. PubMed ID: 31211344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decline in Weight and Incident Mild Cognitive Impairment: Mayo Clinic Study of Aging.
    Alhurani RE; Vassilaki M; Aakre JA; Mielke MM; Kremers WK; Machulda MM; Geda YE; Knopman DS; Petersen RC; Roberts RO
    JAMA Neurol; 2016 Apr; 73(4):439-46. PubMed ID: 26831542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study.
    Pietrzak RH; Lim YY; Neumeister A; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Restrepo C; Martins RN; Masters CL; Villemagne VL; Rowe CC; Maruff P;
    JAMA Psychiatry; 2015 Mar; 72(3):284-91. PubMed ID: 25629787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.